FREE
FREE company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
31 articles
Price performance
Recent trading
Newsroom
Latest FREE coverage
Museum to Host Asian Cultural
[ad_1] (NewMediaWire) – June 25, 2023 – Glendale, CA – The Martial Arts History Museum is proud to host “Dragonfest,” the world’s most popular martial arts expo, on August 5, 2023, at the Glendale Civic Auditorium in Glendale, CA. Nicknamed the “Comic-Con of the Martial Arts,” Dragonfest is the biggest gathering of martial arts stars, ...
123 Profit by Aidan Booth & Steve Clayton Releases Profit Lab Training 3-Step System
[ad_1] Los Angeles, CA – (NewMediaWire) – January 10, 2023 – (NyPressWire) – 123 PROFIT LAUNCHES FREE WEBINARS ON ONLINE BUSINESS OPPORTUNITY TO MAKE MONEY ONLINE IN 2023 Entrepreneur Aidan Booth of 123 Profit announces series of webinars explaining the 3-step system to build an online business. Digital marketing entrepreneur Aidan Bo
The World's Greatest Martial Arts Expo, Dragonfest, is coming to Glendale
[ad_1] (NewMediaWire) – July 24, 2022 – Burbank, CA – The Martial Arts History Museum is proud to host “Dragonfest,” the world’s most popular martial arts expo, on August 6, 2022, at the Glendale Civic Auditorium in Glendale, CA. Nicknamed the “Comic-Con of the Martial Arts,” Dragonfest is the biggest gathering of martial arts stars, ...
Museum Releases Newest Edition to Biography Series
[ad_1] (NewMediaWire) – January 02, 2021 – Burbank, CA – He is considered the most recognizable Asian bad guy in films. With his shaved head and awesome gouache, he has put fear into the hearts of viewers in over 60 films. Black Belt magazine even calls him the scariest man alive. He’s mean, he’s cruel, ...
Tackling triple-negative breast cancer by blocking 2 key survival pathways
[ad_1] Triple-negative breast cancer is the hardest type of the illness to deal with as a result of it lacks estrogen and progesterone receptors and it doesn’t over-express HER2, making it unresponsive to focused therapies. Now, a workforce of researchers led by Princeton University have promising early proof {that a} recombinant protein may block two ...
J&J takes stake in Locus’ CRISPR-based ‘Pac-Man’ antimicrobials
[ad_1] Just over a yr after its first-round financing, CRISPR firm Locus Biosciences has signed up Johnson & Johnson as its first massive pharma accomplice and pocketed a $20 million upfront payment. While most CRISPR firms are taking a look at making use of the CRISPR-Cas9 gene-editing know-how to human illnesses, Locus is taking a ...
.jpg&w=3840&q=75)
After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal
[ad_1] French Big Pharma Sanofi is strolling away from a coronary heart drug illness pact with MyoKardia forward of knowledge readouts coming later this yr. In typical biotech PR spin, MyoKardia labored the information as it “regaining the rights back” to those packages, however in actuality, Sanofi wished out of the pact that it initially ...
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline
[ad_1] Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline. Staten has quietly established itself in the Dutch biotech scene over the past four years. Over that time, ...
Harpoon files $86M IPO to help fund its T-cell engager platform
[ad_1] Fresh off elevating $70 million by a collection C spherical simply over a month in the past, Harpoon Therapeutics introduced it should go public with an $86.25 million IPO to additional help its portfolio of early-stage T-cell engagers geared toward strong tumors. The South San Francisco-based firm filed confidentially with the SEC in late ...
Innovent buys Chinese rights to Incyte drugs for $40M upfront
[ad_1] Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in growth at Incyte. The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs which might be in section 2 and 3 testing within the West. China’s Innovent put ...
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
[ad_1] Australian biotech Imugene says its HER2 vaccine hit the mark in a part 1b trial, establishing a part 2 examine that may start recruiting sufferers in the brand new yr. The first tranche of data from the 14-patient trial comes from the primary 10 evaluable topics who got the HER-Vaxx vaccine at three doses ...
Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
[ad_1] Entrada Therapeutics has debuted with a $59 million sequence A and a plan to ship biologic therapies intracellularly to deal with uncommon and deadly monogenic illnesses. The Boston-based firm will start by tasking its delivery platform for enzyme substitute therapies, protein-protein interplay inhibitors and nucleic acids—together with in an undisclo
Idorsia's selatogrel hits goals in phase 2 cardiovascular trials
[ad_1] Idorsia's P2Y12 receptor antagonist selatogrel has considerably inhibited platelet aggregation in two phase 2 trials. The major endpoint successes in sufferers with secure coronary artery illness (CAD) or acute myocardial infarction (AMI) set Idorsia as much as plan the initiation of a phase 3 examine. Switzerland’s Idorsia, which spun out of Actelion
Sophiris slides on prostate cancer data but vows to press on
[ad_1] Sophiris Bio is adamant that it's going to advance its lead drug topsalysin into section 3 testing, after a second dose confirmed no extra profit in a prostate cancer trial. The firm insists that the midstage data offered after a single administration of the drug is sufficient to warrant a late-stage program. Shares within ...
Lexicon pain drug advances after clearing early clinical test
[ad_1] A part 1a trial of Lexicon Pharmaceuticals’ LX9211 has met its main aims. The examine discovered the AAK1 inhibitor was effectively tolerated, teeing Lexicon as much as advance the neuropathic pain prospect. Lexicon licensed LX9211 from Bristol-Myers Squibb in 2016 after working with the Big Pharma to characterize the AAK1 goal via a neuroscience ...
Roivant strikes broad pipeline pact with Daiichi
[ad_1] Roivant has secured an choice to license a stream of medication from Daiichi Sankyo. The deal is the primary time Roivant has fashioned a framework to facilitate the continued in-licensing of medication from an organization relatively than picked up belongings on an advert hoc foundation. Through the deal, Roivant has gained the choice to ...
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris
[ad_1] Chugai has the optimistic part 3 knowledge it must file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum dysfunction (NMOSD), a rare autoimmune illness, subsequent yr. The Japanese drugmaker now has two optimistic part 3 research backing the efficacy and security of the antibody in the dysfunction, which causes irrita
G1 tanks after placebo beats drug in cancer response rate test
[ad_1] G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo towards a number of efficacy measures in section 2. Trilaciclib carried out nicely towards its neutropenia-related major endpoints however fell brief in phrases of response rate, prompting traders to ship G1's stock down 26%. North Carolina-based G1 designed the section 2 to evaluate
Put Your Money Where Your Mouth Is: 5 Tips to Pinpoint the Best Online Stock Broker
[ad_1] Before you dive into the world of stock buying and selling, you will have to choose a dealer that aligns along with your particular monetary objectives. If you're buying and selling choices, for instance, the proper platform for you will not be the similar one for somebody who's forex buying and selling, or brief ...
How neurons fend off Alzheimer’s with a cellular broom that clears the toxic tau protein
[ad_1] When the protein tau builds up inside the neurons of the mind, the cells grow to be impaired and ultimately die in a course of that’s been implicated in Alzheimer’s and different neurodegenerative ailments. But some neurons by no means get clogged up with tau—and a workforce of scientists led by the Columbia University ...
Make Money and be Socially Responsible (2018)
[ad_1] Have you heard the newest in investing? ALSO READ: How to become a stockbroker: How-to guide with examples “Robo-advisors” are all the fashion for buyers in 2018 – 2019. But which one is finest for you? There is Wealthsimple that means that you can make investments as a lot, or as little, as you ...
.jpg&w=3840&q=75)
Sensorion’s vertigo drug hits tolerability endpoint in phase 2
[ad_1] A phase 2a trial of Sensorion’s vertigo seliforant has met its major tolerability endpoint. The trial discovered the histamine kind 4 receptor antagonist had no impact on vigilance and cognitive efficiency, suggesting it could have an edge over present vertigo remedies comparable to meclizine. Meclizine, a histamine H1 receptor antagonist, is used to
Get the best Tax Refund (and file for FREE)
[ad_1] Congratulations! ALSO READ: Socially Responsible Investing: Does is really work? You have efficiently made it to maturity. You at the moment are the proud proprietor of a… 9 to 5 job Mountain of bills Mild case of tension and depression And since we're nonetheless a good distance from April 15th… …you've [probably] fully forgotten ...
CRISPR controls obesity in mice by amplifying rather than editing genes
[ad_1] The genes SIM1 and MC4R regulate food consumption by signaling the sensation of being full, which is why mutations in these genes are related to extreme obesity. Even if simply one of many two copies of these genes {that a} person inherits from each dad and mom is unhealthy, she or he will most ...
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint
[ad_1] Sunovion Pharmaceuticals and PsychoGenics unveiled constructive phase 2 outcomes for a brand new schizophrenia therapy that doesn't bind to the mind’s dopamine receptors. While its precise mechanism of motion is unknown, the 2 firms imagine that SEP-363856 prompts hint amine-associated receptor 1 (TAAR1) along with the serotonin receptor 5-HT1A with o
Amag merges with Perosphere, adding NOAC antidote
[ad_1] Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its rising hematology enterprise. The phrases of the deal see Amag making an upfront cost of $50 million for privately-held Perosphere, assuming $18.5 million of its debt and different liabilities, and committing to pay as much ...
.jpg&w=3840&q=75)
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
[ad_1] NeuroRx is planning to maneuver NRX-101 into part 2b/3 after detecting indicators of efficacy in a feasibility trial in patients with suicidal bipolar depression. The small part 2 feasibility research linked fixed-dose mixture NRX-101 to improved scores on a depression ranking scale. Delaware-based NeuroRx primarily designed the trial to evaluate blo
Could a once-abandoned obesity drug be revived in osteoporosis?
[ad_1] Irisin, the as soon as much-hyped however controversial “exercise hormone” that researchers had hoped would be an efficient obesity remedy, might make a comeback—this time in bone strengthening. In a examine revealed in the journal Cell, a staff led by scientists at Harvard University Medical School discovered that injections of irisin in mice elevat
Biofrontera cleared of wrongdoing in Nasdaq IPO
[ad_1] An impartial evaluation has cleared Biofrontera of wrongdoing associated to its U.S. IPO. Shareholders had accused Biofrontera of appearing opposite to its duties when it priced and bought stock in the U.S. Biofrontera, which was elevating cash to run dermatological scientific trials, rejected the accusations however labored with a company that repres
Free for college students. (What about the rest of us?)
[ad_1] Have you ever heard the expression “a little goes a long way”? ALSO READ: Stash App Review: Free $5 when you open account today Everyone has heard of that expression as a result of it's true. Do you battle time after time to construct your financial savings? If you battle, that's since you are ...
GenSight rebuilds its case for LHON gene therapy, eyeing filing next year
[ad_1] GenSight Biologics has reported new knowledge from its section 3 program for GS010, its gene remedy for an ultrarare eye illness, sparking one other uptick in its share value. The French biotech says the newest outcomes from its REVERSE trial of GS010 (rAAV2-ND4) in Leber hereditary optic neuropathy (LHON) present quality-of-life advantages in suffere